Risk factors

Linde faces heavy exposure to energy cost volatility and supply disruptions since energy is its largest production expense. International operations across 80 countries expose Linde to severe currency, geopolitical, and trade regulatory risks. Goodwill and intangible assets totaling $28 billion create significant impairment vulnerability if market conditions deteriorate.

Concentrated exposure to temperature-controlled warehousing, high utility and labor costs, rapid recent growth via acquisitions, and transition away from Bay Grove.

Lemonade faces heavy losses, with an accumulated deficit of $1,298.8 million as of December 31, 2024. Growth depends on customer acquisition, retention, and expanding average premium per user. Operations rely heavily on proprietary artificial intelligence algorithms for pricing and claims processing. Geographic concentration in California, New York, and Texas exposes the company to regional catastrophe risks.

Dependence on PMF partners and third-party manufacturers for just-in-time radiopharmaceutical distribution.

Laird Superfood faces intense competition in the natural and organic food and beverage industry. The company relies heavily on third-party co-manufacturers, distributors like UNFI and KeHE, and retailers like Costco and Amazon. Key product lines rely on raw materials like coconut milk powder and organic coconut sugar sourced internationally. The business depends on founders Laird Hamilton and Gabrielle Reece for brand identity.

Revenue depends heavily on business formations and converting customers into recurring subscribers, which generated approximately 64% of 2024 revenue.

Mattel faces severe customer concentration with Walmart, Target, and Amazon generating 44% of total net sales. Mattel carries $2.33 billion in debt and $1.40 billion in revolving credit commitments. International markets represent 41% of net sales, exposing Mattel to currency and geopolitical risks.

Madrigal is a newly commercial-stage biopharmaceutical company focused entirely on the market acceptance and commercialization of Rezdiffra for MASH. The company relies on single-product viability, third-party manufacturers, specialty pharmacies, and external capital to fund operations.

MIMEDX relies heavily on human tissue supply, GPO contracts representing 76% of sales, and third-party reimbursement for products like EPIFIX.

This filing reflects a company heavily exposed to agricultural commodity costs, alcohol regulations, and consumer shifts.

The risk section is dominated by financial leverage with $2.4 billion in borrowings, extensive international trade exposures, and execution risks surrounding the planned 2026 spin-off of the Food Processing business.

Radiation safety, radioactive-material regulation, and public acceptance of nuclear power dominate operational exposure.